Imbruvica ibrutinib: Phase Ib/II started

Pharmacyclics began the open-label, U.S. Phase Ib/II PCYC-1135-CA trial to evaluate oral Imbruvica ibrutinib once daily in combination with IV MEDI4736 from AstraZeneca plc (LSE:AZN; NYSE:AZN, London, U.K.) in about 160 patients with non-small cell lung cancer (NSCLC), breast cancer and pancreatic cancer. Pharmacyclics’ Imbruvica is approved in the U.S. to treat Waldenstrom’s macroglobulinemia and chronic lymphocytic leukemia (CLL) in patients with a chromosome 17p deletion and patients who have received >1 prior therapy. The drug has accelerated approval to treat mantle cell lymphoma (MCL). MEDI4736 is a human IgG1 mAb targeting programmed cell death 1 ligand 1 ( PD-L1; B7-H1; CD274). ...